Progressos recentes e novas perspectivas em farmacoterapia da obesidade

Rucker D, 2007, Long term pharmacotherapy for obesity and overweight: updated meta-analysis, BMJ, 335, 1194, 10.1136/bmj.39385.413113.25

Coutinho W, 2009, The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions, Arq Bras Endocrinol Metabol, 53, 262, 10.1590/S0004-27302009000200018

Sjöström L, 2007, Swedish Obese Subjects Study: Effects of bariatric surgery on mortality in Swedish obese subjects, N Engl J Med, 357, 741, 10.1056/NEJMoa066254

Weintraub M, 1992, Long-term weight control study: I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo, Clin Pharmacol Ther, 51, 586, 10.1038/clpt.1992.69

Connolly HM, 1997, Valvular heart disease associated with fenfluramine-phentermine, N Engl J Med, 337, 581, 10.1056/NEJM199708283370901

Smith SR, 2009, Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women, Obesity, 17, 494, 10.1038/oby.2008.537

Bays HE, 2009, Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease, Expert Rev Cardiovasc Ther, 7, 1429, 10.1586/erc.09.123

Astrup A, 2008, Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease, Obesity, 16, 1363, 10.1038/oby.2008.56

Astrup A, 2008, Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1906, 10.1016/S0140-6736(08)61525-1

Degn KB, 2004, One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes, Diabetes, 53, 1187, 10.2337/diabetes.53.5.1187

Vilsbøll T, 2007, Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes, Diabetes Care, 30, 1608, 10.2337/dc06-2593

Flint A, 1998, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans, J Clin Invest, 101, 515, 10.1172/JCI990

Astrup A, 2009, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study, Lancet, 374, 1606, 10.1016/S0140-6736(09)61375-1

Padwal R, 2008, Cetilistat, a new lipase inhibitor for the treatment of obesity, Curr Opin Investig Drugs, 9, 414

Kopelman P, 2010, Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical), Obesity, 18, 108, 10.1038/oby.2009.155

Klonoff DC, 2008, Drugs in the pipeline for the obesity market, J Diabetes Sci Technol, 2, 913, 10.1177/193229680800200525

Mancini MC, 2006, Investigational therapies in the treatment of obesity, Expert Opin Investig Drugs, 15, 897, 10.1517/13543784.15.8.897

Jones D, 2009, Novel pharmacotherapies for obesity poised to enter market, Nat Rev Drug Discov, 8, 833, 10.1038/nrd3044

Zanella MT, 2009, Emerging drugs for obesity therapy, Arq Bras Endocrinol Metabol, 53, 271, 10.1590/S0004-27302009000200019

Anderson JW, 2002, Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial, Obes Res, 10, 633, 10.1038/oby.2002.86

Lee MW, 2009, Naltrexone for the treatment of obesity: review and update, Expert Opin Pharmacother, 10, 1841, 10.1517/14656560903048959

Simpson KA, 2009, Hypothalamic regulation of food intake and clinical therapeutic applications, Arq Bras Endocrinol Metabol, 53, 120, 10.1590/S0004-27302009000200002

Greenway FL, 2009, Rational design of a combination medication for the treatment of obesity, Obesity, 17, 30, 10.1038/oby.2008.461

Padwal R, 2009, Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity, Curr Opin Investig Drugs, 10, 1117

Greenway FL, 2009, Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo, J Clin Endocrinol Metab, 94, 4898, 10.1210/jc.2009-1350

Oommen KJ, 1999, Zonisamide: a new antiepileptic drug, Clin Neuropharmacol, 22, 192

Gadde KM, 2003, Zonisamide for weight loss in obese adults: a randomized controlled trial, JAMA, 289, 1820, 10.1001/jama.289.14.1820

McElroy SL, 2006, Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial, J Clin Psychiatry, 67, 1897, 10.4088/JCP.v67n1209

Mancini MC, 2006, Pharmacological treatment of obesity, Arq Bras Endocrinol Metabol, 50, 377, 10.1590/S0004-27302006000200024

Astrup A, 2004, Topiramate: a new potential pharmacological treatment for obesity, Obes Res, 167S, 10.1038/oby.2004.284

Leombruni P, 2009, Treatment of obese patients with binge eating disorder using topiramate: a review, Neuropsychiatr Dis Treat, 5, 385, 10.2147/NDT.S3420

Ravussin E, 2009, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy, Obesity, 17, 1736, 10.1038/oby.2009.184

Smith SR, 2008, Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity, Diabetes Care, 31, 1816, 10.2337/dc08-0029

Heymsfield SB, 1999, Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial, JAMA, 282, 1568, 10.1001/jama.282.16.1568

Rosenbaum M, 2005, Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight, J Clin Invest, 115, 3579, 10.1172/JCI25977

Trevaskis JL, 2008, Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms, Endocrinology, 149, 5679, 10.1210/en.2008-0770

2010